Tag: ALKtALK
- ALK Experts
- ALK International
- ALK Positive News
- Clinical Trials
- Government
- Living with ALK+
- Nutrition
- Patient & Care Partner Stories
- Powered By Patients
- Recipes
- Research
-
ALKtALK: Dr. Kyle Concannon
Could CAR T-Cell Therapy Be the Future of Lung Cancer Treatment? CAR T-cell therapy has transformed treatment for some blood cancers, but could this innovative approach also work for lung cancer? Researchers are exploring how specially engineered immune cells might target cancer cells that survive targeted therapies, potentially offering a new strategy for overcoming treatment…
-
ALKtALK: What’s New in ALK+ Research
Dr. Ken Culver, Executive Director and Medical Director of ALK Positive, helps kick off Lung Cancer Awareness Month (LCAM) with an update for the ALK-positive community on the latest research developments. Dr. Culver walks through current clinical trials and several research projects supported by or directly connected to the ALK-positive community. The presentation also shares…
-
ALKtALK: Dr. Eric Singhi
ALKtALK is back for Season 7! Dr. Eric Singhi is a thoracic medical oncologist at MD Anderson Cancer Center with a passion for caring for people with lung cancer, not just treating the cancer itself. In this Season 7 premiere of ALKtALK, Dr. Singhi joins the ALK-positive community for a wide-ranging conversation filled with practical…
-
ALKtALK: AI in your Corner: One Advocate’s Guide to Using AI Tools for Your Cancer Care.
You asked and we listened- this is yet another ALKtALK you won’t want to miss! We’ll be joined by a fellow ALK-positive patient who shares how AI tools help him manage his cancer care- from preparing for appointments to understanding scan reports and side effect management. With prior professional experience navigating privacy and security tradeoffs,…
-
ALKtALK: Live from ASCO with Dr. Christine Lovly!
Join ALKtALK to hear from ALK Positive’s Director of Research and Clinical Affairs. Dr. Ken Culver will provide updates on the essential work of ALK Positive’s Medical Committees, the research projects you helped power, and the bold priorities ahead.
-
ALKtALK with Dr. Ken Culver
Join ALKtALK to hear from ALK Positive’s Director of Research and Clinical Affairs. Dr. Ken Culver will provide updates on the essential work of ALK Positive’s Medical Committees, the research projects you helped power, and the bold priorities ahead.
-
ALKtALK: Brain Progression
ALKtALK with Dr. Timothy Burns and Dr. Joshua Palmer Navigating Brain Progression in ALK+ Cancer: TKIs, Radiation, LMD, and More For ALK-positive patients, brain progression is one of the most feared parts of a lung cancer diagnosis. When the progression happens, the questions come fast: Do I stay on my current TKI? Do I radiate?…
-
ALKtALK: Dr. Alex Spria
ALKtALK with Dr. Alex Spria Inside the Pipeline: TRI-611 and ALK+ Treatment Strategies In this ALKtALK, we’re joined by Alexander Spira, MD, PhD, FASCO, medical oncologist at Virginia Cancer Specialists and member of the ALK Positive Scientific Advisory Board. Dr. Spira shares insights and expertise on two clinical trials for ALK-positive patients—TRI-611 and Gilteritinib—and what…
-
ALKtALK: Dr. Jonathan Riess
Navigating ALK-positive Clinical Trials: Facts Timelines, and Real Expectations On Sunday, March 29 at 7:00pm ET, Dr. Riess and Johanna Han joined ALKtALK for an educational conversation focused on ALK+ cancer clinical trials, including single-patient INDs (Investigational New Drugs)—what they are, what they are not, and what patients and care partners should realistically expect when…
-
ALKtALK: Dr. Alex Drilon
New Data, New Directions: Neladalkib (NVL-655) and Precision Oncology in ALK-positive Cancer Sunday, March 1st at 7:00pm ET, Alexander Drilon, MD joined ALKtALK to present and discuss the latest data on neladalkib (NVL-655). The conversation included a review of emerging efficacy and safety data, along with discussion of how promising therapies move from clinical trials toward broader…
-
ALKtALK: Treatment Roundtables
ALKtALK presents: tALKing About Treatment: Roundtable Discussion Groups Sunday, February 15th is our annual treatment roundtable discussion — a longtime favorite within the ALK community. Treatment is not a one-size-fits-all prescription. Some of us take a TKI, some are on chemotherapy, others combine treatments — most of us moving between approaches over time. Regardless of…
-
Start 2026 with ALKtALK: A conversation with Dr. Alice Shaw
Sunday, January 11th. Dr. Alice Shaw is a world-renowned thoracic oncologist and one of the most influential leaders in lung cancer research. Often referred to as the “Queen of ALK,” Dr. Shaw has been instrumental in advancing multiple ALK targeted therapies and shaping the standard of care for ALK-positive cancer. She is a longtime champion…